Argus upgraded Elevance Health (ELV) to Buy from Hold with a $450 price target Light Up your Portfolio with Spark:Easily identify stocks' risks ...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunome (IMNM – Research Report) and Monte Rosa ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers ...

Elevance Health (NYSE:ELV – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Wednesday. A number ...

Elevance Health Inc. closed 26.44% below its 52-week high of $567.26, which the company reached on September 3rd.

Regulatory changes under Trump's administration and AI integration are key factors influencing Elevance Health's future ...

Shares of Elevance Health, Inc. (NYSE:ELV – Get Free Report) have been assigned an average rating of “Moderate Buy” from the ...

Elevance Health ELV has outperformed the market over the past 15 years by 2.24% on an annualized basis producing an average ...

Most readers would already know that Elevance Health's (NYSE:ELV) stock increased by 9.5% over the past three months. Since the market usually pay for a company’s long-term financial health, we ...

Rep. Jefferson Shreve recently purchased shares of Elevance Health valued between $15,001 and $50,000. The disclosure, filed on March 9, also revealed additional investments in major companies, ...

Health Care Service Corp., Elevance Health and Aetna  — accounted for more than 40% of Hinge's revenue in 2024.